These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16291891)

  • 1. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.
    Zajicek JP; Sanders HP; Wright DE; Vickery PJ; Ingram WM; Reilly SM; Nunn AJ; Teare LJ; Fox PJ; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1664-9. PubMed ID: 16291891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
    Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
    Freeman RM; Adekanmi O; Waterfield MR; Waterfield AE; Wright D; Zajicek J
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Nov; 17(6):636-41. PubMed ID: 16552618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
    Zajicek JP; Hobart JC; Slade A; Barnes D; Mattison PG;
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1125-32. PubMed ID: 22791906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J; Hoogervorst EL; Reif M; Kalkers NF; Van Loenen AC; Staats PG; Gorter RW; Uitdehaag BM; Polman CH
    Neurology; 2002 May; 58(9):1404-7. PubMed ID: 12011290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT; Robson P; House H; Makela P; Aram J
    Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ; Nurmikko TJ; Friede T; Young CA
    Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
    Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT; Makela P; Robson P; House H; Bateman C
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cannabis on tremor in patients with multiple sclerosis.
    Fox P; Bain PG; Glickman S; Carroll C; Zajicek J
    Neurology; 2004 Apr; 62(7):1105-9. PubMed ID: 15079008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
    Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
    Smith PF
    Curr Opin Investig Drugs; 2002 Jun; 3(6):859-64. PubMed ID: 12137404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.